<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; PPCO</title>
	<atom:link href="http://www.stockbloghub.com/tag/ppco/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Holdings to Buy Penwest Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2010/08/20/endp-endo-pharmaceuticals-holdings-to-buy-penwest-pharmaceuticals/48631</link>
		<comments>http://www.stockbloghub.com/2010/08/20/endp-endo-pharmaceuticals-holdings-to-buy-penwest-pharmaceuticals/48631#comments</comments>
		<pubDate>Fri, 20 Aug 2010 15:44:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Penwest Pharmaceuticals Company]]></category>
		<category><![CDATA[PPCO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48631</guid>
		<description><![CDATA[In a bid to sustain and drive growth in the area of pain management, Endo Pharmaceuticals Holdings Inc. (ENDP) recently agreed to acquire drug developer Penwest Pharmaceuticals Co. (PPCO). Through this deal, Endo Pharma will gain full access to a painkiller that was being co-developed by the companies. The deal, worth approximately $144 million or $5.00 per share in cash, has been approved by the Boards of both companies. The companies have been co-developing an extended-release version of Opana (Opana ER) for treating moderate to severe pain in patients in need of continuous opioid treatment. Under the terms of the agreement, Endo will commence an all-cash tender offer shortly to purchase all the outstanding common stock of Penwest. The tender offer price of $5.00 per share represents a premium of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/20/endp-endo-pharmaceuticals-holdings-to-buy-penwest-pharmaceuticals/48631/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

